Komori
Astellas Pharma (4503) · RiskReframed

Reputational Risk from Failure to Meet ESG Commitments

First written in FY2024. 1 of 2 entries say "Reframed", first in FY2026-H1. Latest entry: FY2026-H1.

2entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY20242024: 120242025: 12025
Same theme, other companies
Risk of business impacts from inadequate response to environmental and social demandsA theme 43 companies write about · 43 as a headwind · 0 as a tailwind

Astellas Pharma moved to the "Worse" side of this theme in 2025.

1 other company's latest entry also says "Reframed".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 43 companies compared. The sentences above are computed from all 43.
Full recordFilings, disclosures and news, newest first
  1. FY2026-H1ReframedAnnual report

    「・サステナビリティに係る外部期待・コミットメントの達成」

    サステナビリティに係る外部期待・コミットメントの達成をグローバル・リスクの対象範囲から除外し、個別部門の管理対象として整理した。必要な対応は継続するとしている。
  2. FY2024First statedAnnual report

    「仮にこれらのコミットメントを達成できなかった場合は、レピュテーションが棄損される場合があります。」

    ESGに関する外部期待及び自社コミットメントの未達が、評判毀損につながるリスクを新たなグローバルリスクとして記載した。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Astellas Pharma's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Reputational Risk from Failure to Meet ESG Commitments | Astellas Pharma Inc. (4503) | Komori